US pharmaceutical company Eli Lilly and Company plans to invest over $1 billion in India over the next few years to set up new contract manufacturing facilities and a manufacturing and quality hub in Hyderabad. The investment will also support the company’s supply chain capabilities in India.
Hyderabad hub
The Hyderabad hub will provide technical oversight for Lilly’s contract manufacturing network across the country. Recruitment for the new facilities is expected to start immediately, with openings in engineering, chemistry, analytical science, quality control and assurance, and management roles.
Since 2020, Lilly has invested more than $55 billion globally in building, expanding, and acquiring manufacturing facilities to support medicines for diabetes, obesity, Alzheimer’s disease, cancer, autoimmune conditions, and other therapies.
Patrik Jonsson, Executive Vice President and President of Lilly International, said the investment reinforces India’s role as a hub for the company’s global manufacturing network.
‘Centre for Healthcare Innovation’
Telangana Chief Minister A. Revanth Reddy said the expansion highlights Hyderabad’s emergence as a centre for healthcare innovation. IT and Industries Minister Sridhar Babu noted that the investment reflects the state’s industrial growth and influence in advanced healthcare manufacturing.
Lilly already has a commercial site in Gurugram and specialised sites in Bengaluru and Hyderabad that support its global operations. The new facilities aim to strengthen local technical capabilities and expand the company’s manufacturing footprint in India.